Archimedes, Inc. Expands Use of Big Data in Healthcare Modeling and Analytics
News Mar 28, 2013
Archimedes, Inc., a healthcare modeling and analytics company, announced today that it is substantially expanding its modeling and analytics solutions. New product offerings and disease models will enable users to more quickly and easily access and analyze information related to their complex questions. Archimedes customers will be able to further enhance their modeling and analytic projects by integrating their own electronic health records (EHR), claims, clinical trial, and pharmacokinetic/pharmacodynamic (PK/PD) simulation outcomes data with data from Archimedes simulations and proprietary algorithms. This integrated data will be accessed and analyzed through novel interfaces that offer near-instant results.
For more than ten years, the company has been working to proactively identify new opportunities where big data can play a role in the healthcare continuum – from research and development to the point of patient care. The advancements, which will become available throughout 2013, represent Archimedes’ continued commitment to its vision of revolutionizing medicine worldwide through mathematics.
“At Archimedes, we are dedicated to harnessing the power of big, real-world data by developing healthcare modeling and analytics tools,” said David Eddy, M.D., Ph.D. founder of Archimedes and pioneer in the area of evidenced-based medicine. “We are continually developing tools that can help researchers, life-science organizations, government agencies, payers, and providers get the most from the available data. Archimedes is excited to announce that, starting today, we will be providing free access through our website to new, easy-to-use tools for addressing some of healthcare’s most complex questions.”
Since inception, Archimedes has been striving to improve efficiencies in the healthcare system by developing quantitative methods for analyzing healthcare decisions at the individual and population levels. The tools, including the new ARCHeS Population Explorer, take modeling and analytics a step further by delivering big data to the fingertips of users, making it easier and faster to gather, enhance, and analyze multiple datasets. In the current era of accountability in medical decision making, it is critical that actionable data analytics tools are made available to the people who need them most.
The Archimedes Model is the most advanced mathematical modeling tool available to answer complex questions regarding health and healthcare. It is a clinically realistic, trial-validated, mathematical model of human physiology, diseases, interventions, and healthcare systems. By using advanced methods of mathematics, computing, and data systems, the Model enables researchers and decision makers to make better informed decisions. Archimedes continually validates the Model by comparing the results of simulated trials to the results of multinational clinical trials and cohort studies. The Model is the foundation behind the various solutions offered by Archimedes – including ARCHeS, the population-focused research platform, and IndiGO, the clinical-decision support tool for use by physicians and patients at the point-of-care.
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
Radioprotective Drugs Assessed Using Human Gut Organ-on-a-ChipNews
Researchers have published a study using an organ-on-a-chip (Organ Chip) model of the human gut that reveals the intestinal blood vessel cells may play an important part in radiation-induced intestinal injury, and it confirms that a potential radioprotective drug, dimethyloxaloylglycine (DMOG), suppresses the intestine’s responses to radiation injury.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE